Novo Nordisk's obesity drug Wegovy debuts in Thailand
Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's local subsidiary said on Monday, marking the injectable drug's first entry into the Southeast Asian market.
Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies from marketing or selling cheaper, unapproved versions of the drugmaker's blockbuster weight loss drug Wegovy and diabetes treatment Ozempic. U.S. District Judge Mark Pittman denied the Outsourcing Facilities Association's bid for a preliminary injunction that would have prevented the FDA from taking action against its members for making copies of semaglutide, the active ingredient in Ozempic and Wegovy.
The Best Stock to Buy With Less Than $60 in the Market Sell-Off
Plenty of stocks with attractive businesses trade on the market for hundreds of dollars per share -- or more. However, it's possible to find excellent stocks that may become undervalued when either the market undergoes a deep correction, including in a bear market, or in company-specific situations where temporary problems seem to hinder the business, muddling its longer-term outlook.
Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?
Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?
Denmark-based pharmaceutical giant Novo Nordisk (NVO 2.66%) has been struggling during the past year. Its financial results -- though strong by comparison to most of its peers -- haven't been as good as investors expected.
Novo Nordisk: Be Greedy When Others Are Fearful
Novo Nordisk is a high-quality biopharma company with a strong diabetes franchise and a booming obesity drug segment, making it an attractive growth play. Following a 50% drop from recent highs, NVO trades at a significant discount compared to historical valuations, presenting a buying opportunity. The company's diverse portfolio, including diabetes, obesity, and rare diseases, ensures robust growth and reduces reliance on any single product.
Down 60%, Is This Growth Stock Too Cheap to Ignore?
In this video, I will cover recent updates regarding Novo Nordisk (NVO 0.48%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
Novo Nordisk (NVO) closed the most recent trading day at $58.33, moving +0.43% from the previous trading session.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (April 2025)
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Novo Nordisk: A Price Too Low To Ignore
Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is disappointing results for its drug trials, though challenges like potential tariffs on Denmark, its home country, also play a part. Yet, the company's robust fundamentals, healthy outlook and attractive market multiples go in its favour, justifying a Buy rating.
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
